NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced an award of a grant from the Bill & Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of the company's vaccine candidate against group B Streptococcus (group B strep or GBS) infection. The investigational vaccine is designed to protect newborns via maternal immunization.
Neonatal GBS infection is a debilitating and often fatal disease with mortality rates of around 6% to 14% of those infected in industrialized countries4 and approximately 14% to 38% of those infected in parts of the developing world.
Copyright RTT News/dpa-AFX